These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 33786990)

  • 1. Adverse drug event risk assessment by the virtual addition of COVID-19 repurposed drugs to Medicare and commercially insured patients' drug regimens: A drug safety simulation study.
    Smith MK; Bikmetov R; Al Rihani SB; Deodhar M; Hafermann M; Dow P; Turgeon J; Michaud V
    Clin Transl Sci; 2021 Sep; 14(5):1799-1809. PubMed ID: 33786990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs.
    Michaud V; Dow P; Al Rihani SB; Deodhar M; Arwood M; Cicali B; Turgeon J
    Clin Transl Sci; 2021 Jan; 14(1):20-28. PubMed ID: 32888379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.
    Prats-Uribe A; Sena AG; Lai LYH; Ahmed WU; Alghoul H; Alser O; Alshammari TM; Areia C; Carter W; Casajust P; Dawoud D; Golozar A; Jonnagaddala J; Mehta PP; Gong M; Morales DR; Nyberg F; Posada JD; Recalde M; Roel E; Shah K; Shah NH; Schilling LM; Subbian V; Vizcaya D; Zhang L; Zhang Y; Zhu H; Liu L; Cho J; Lynch KE; Matheny ME; You SC; Rijnbeek PR; Hripcsak G; Lane JC; Burn E; Reich C; Suchard MA; Duarte-Salles T; Kostka K; Ryan PB; Prieto-Alhambra D
    BMJ; 2021 May; 373():n1038. PubMed ID: 33975825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy.
    Al Rihani SB; Smith MK; Bikmetov R; Deodhar M; Dow P; Turgeon J; Michaud V
    J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32785135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
    Gérard A; Romani S; Fresse A; Viard D; Parassol N; Granvuillemin A; Chouchana L; Rocher F; Drici MD;
    Therapie; 2020; 75(4):371-379. PubMed ID: 32418730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
    Zekarias A; Watson S; Vidlin SH; Grundmark B
    Drug Saf; 2020 Dec; 43(12):1309-1314. PubMed ID: 32978702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
    Sarayani A; Cicali B; Henriksen CH; Brown JD
    Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
    Zequn Z; Yujia W; Dingding Q; Jiangfang L
    Eur J Pharmacol; 2021 Feb; 893():173813. PubMed ID: 33345848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
    Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.
    Shah RR
    J Clin Pharm Ther; 2021 Feb; 46(1):17-27. PubMed ID: 32981089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem.
    Fresse A; Viard D; Romani S; Gérard A; Lepelley M; Rocher F; Salem JE; Drici MD;
    Int J Cardiol; 2021 Feb; 324():255-260. PubMed ID: 33075384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile of COVID-19 drugs in a real clinical setting.
    Chiu MN; Bhardwaj M; Sah SP
    Eur J Clin Pharmacol; 2022 May; 78(5):733-753. PubMed ID: 35088108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
    Olagunju A; Fowotade A; Olagunoye A; Ojo TO; Adefuye BO; Fagbamigbe AF; Adebiyi AO; Olagunju OI; Ladipo OT; Akinloye A; Adeagbo BA; Onayade A; Bolaji OO; Happi C; Rannard S; Owen A
    Trials; 2021 Jan; 22(1):3. PubMed ID: 33397457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.
    Diaby V; Almutairi RD; Chen Z; Moussa RK; Berthe A
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):159-168. PubMed ID: 33186061
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
    Meriglier E; Rivoisy C; Hessamfar M; Bernard N; Aureau I; Lapoirie J; Contis A; Sacher F; Sacristan B; Lahouati M; Pedeboscq S; Vandenhende MA; Bouchet S; Bonnet F
    J Antimicrob Chemother; 2021 Jan; 76(2):482-486. PubMed ID: 33221868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
    Vernaz N; Agoritsas T; Calmy A; Gayet-Ageron A; Gold G; Perrier A; Picard F; Prendki V; Reny JL; Samer C; Stirnemann J; Vetter P; Zanella MC; Zekry D; Baggio S
    Swiss Med Wkly; 2020 Dec; 150():w20446. PubMed ID: 33382449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review.
    Kröker A; Tirzīte M
    Respir Res; 2021 Nov; 22(1):304. PubMed ID: 34838020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QTc prolongation during antiviral therapy in two COVID-19 patients.
    Zhu S; Wang J; Wang Y; Chu J; Liu Y; Chen X; Chen X
    J Clin Pharm Ther; 2020 Oct; 45(5):1190-1193. PubMed ID: 32779770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective.
    Beyzarov E; Chen Y; Julg R; Naim K; Shah J; Gregory WW; Ayoub A; Caubel P
    Drug Saf; 2021 Jan; 44(1):95-105. PubMed ID: 33354753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.